Beigene Ltd (BGNE) CEO John Oyler Sold $13.5 million of Shares

GuruFocus.com
0

- By insider

CEO of Beigene Ltd (BGNE) John Oyler sold 144,000 shares of BGNE on 12/08/2017 at an average price of $93.95 a share. The total sale was $13.5 million.

BeiGene Ltd is a clinical-stage biopharmaceutical company engaged in the discovery & development of molecularly targeted & immuno-oncology drugs for the treatment of cancer. Its product includes BGB-3111, BGB-283 and BGB-290 and one immuno-oncology agent. BeiGene Ltd has a market cap of $4.35 billion; its shares were traded at around $95.98 with and P/S ratio of 20.19.


CEO Recent Trades:

  • CEO, 10% Owner John Oyler sold 144,000 shares of BGNE stock on 12/08/2017 at the average price of $93.95. The price of the stock has increased by 2.16% since.

  • CEO, 10% Owner John Oyler sold 85,906 shares of BGNE stock on 11/29/2017 at the average price of $84.66. The price of the stock has increased by 13.37% since.

  • CEO, 10% Owner John Oyler sold 150,957 shares of BGNE stock on 11/15/2017 at the average price of $80.5. The price of the stock has increased by 19.23% since.

Directors and Officers Recent Trades:

  • CMO, Hematology Jane Huang sold 1,100 shares of BGNE stock on 12/04/2017 at the average price of $86. The price of the stock has increased by 11.6% since.

  • CMO, Hematology Jane Huang sold 1,600 shares of BGNE stock on 11/20/2017 at the average price of $86.25. The price of the stock has increased by 11.28% since.

  • CMO, Immuno-oncology Amy C. Peterson sold 3,601 shares of BGNE stock on 11/13/2017 at the average price of $82.96. The price of the stock has increased by 15.69% since.

For the complete insider trading history of BGNE, click here

.This article first appeared on GuruFocus.


Advertisement

Recommended Stories